Hyloris Reports Half-Year 2020 Financial Results and Business Highlights
Successfully raised €80 million through public listing on Euronext Brussels and private placement
Funding of all development portfolio secured up until launch
Funding available for business development opportunities
Management to host a conference call at 2:00pm CEST today
Liège, Belgium – 6 August 2020 – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL) (“Hyloris” and/or the “Company”), an early-stage innovative specialty pharmaceutical company focused on adding value to the healthcare system by reformulating well-known pharmaceuticals, today provides a business update and its consolidated financial results for the first half of 2020, prepared in accordance with IFRS as adopted by the European Union, and an outlook for the second half of 2020. The full interim condensed financial report is available on the Company’s website.
Stijn Van Rompay, Chief Executive Officer of Hyloris, commented: “Having successfully completed our public listing on Euronext Brussels, we are well positioned to deliver our goal to bring reformulated drugs with added value to the healthcare system to market as quickly as possible. We have a clear strategic vision to accomplish this and look forward to making progress through the development of our existing portfolio of product candidates, the establishment of a commercial team in the United States for our IV Cardiovascular portfolio and the potential organic or acquisition-driven expansion of our pipeline.”
First half 2020 operational highlights and relevant post-period events
Hyloris continued to successfully develop its product portfolio over the first six months of 2020. The following elements were identified as key highlights:
IV1 Cardiovascular portfolio
- In March, the US FDA approved a Sotalol IV label expansion to include rapid loading of patients starting on sotalol. The commercialization of this new label expansion in the United States will start in H2 2020.
- Oral Sotalol is a commonly used drug for the maintenance of sinus rhythm in patients with atrial fibrillation with a black box warning requiring patients to be continuously monitored for a period of days when initiating the therapy.
- This novel Sotalol IV loading indication can decrease the length of hospital admission and potentially significantly decrease overall cost of care, while improving patient satisfaction and safety.
Other Reformulation portfolio
- Maxigesic® IV2 was launched in Australia, New Zealand and the UAE in June 2020 by Hyloris’ partner AFT Pharmaceuticals (“AFT”).
- Hyloris will receive a part of the margin generated in all countries were Maxigesic® IV will be commercialized except in Australia and New Zealand.
- Launch should support additional market approvals in the coming months.
- June – AFT signed an exclusive distribution agreement for the commercialization of Maxigesic® IV in four western European countries (Germany, France, Italy and Austria) with Austria’s Ever Pharma.
- Commercialization could start in late 2020 in Germany and Austria.
- July – Completion of the enrolment of the open-label, multiple-dose, single arm exposure clinical Phase III trial of Maxigesic® IV in 232 patients with acute pain following orthopedic, general or plastic surgery.
- This second Phase III study was undertaken in New Zealand and the United States and aims at determining the tolerability of repeated doses of Maxigesic® IV over an extended period of exposure.
- An earlier Phase III clinical trial conducted in 276 patients (for the treatment of acute postoperative pain after foot surgery (bunionectomy)) found that Maxigesic® IV provided significantly better pain relief than either Paracetamol IV (acetaminophen) or Ibuprofen IV alone at the same doses.
- July – AFT signed a license and supply agreement for the commercialization of Maxigesic® for Bulgaria, Cyprus, the Czech Republic, Hungary, Romania and Slovakia with the Cyprus based multinational pharmaceutical company Medochemie.
- Commercialization in these countries is expected to start in 2021
Established Market portfolio
- February - Hyloris sold all rights, titles and interest in the product HY-REF-038 in vial form to Alter Pharma3, while retaining all rights to the Prefilled Syringe, for a consideration (of the transferred intellectual property rights) of € 1.4 million. The generic vial form is currently already commercially available in the United States.
- During the first quarter the ANDA4 application for HY-EMP-016 was submitted by Hyloris’ partner Perrigo at the FDA. Approval is expected in 2021.
Corporate highlights
- Hyloris successfully raised €79.54 million gross proceeds.
- In March and April, the Company issued convertible bonds totaling €15.15 million.
- On June 29, the Company completed an Initial Public Offering on Euronext Brussels, raising a total of €61.81 million.
- All bonds were converted into equity on June 30, at a 30% discount of the IPO price.
- On July 30, the Company received an additional €2.58 million from the exercise of the over-allotment option, bringing the total gross proceeds of the IPO to €64.39 million.
- Hyloris expanded its senior management team with the recruitment of an experienced Chief Legal Officer and Chief Financial Officer, who both bring extensive industry expertise in strategic legal, finance and business development planning and execution.
- The Company also expanded its Board of directors with the addition of Leon Van Rompay and three independent directors, namely Carolyn Myers, James Gale and Marc Foidart.
Selected financial information
| In € thousand | June 30, 2020 | June 30, 2019 | December 31, 2019 | |
| Revenue | 82 | 75 | 91 | |
| Research and development expenses | (1,172) | (819) | (4,577) | |
| General and administration expenses | (2,454) | (316) | (808) | |
| Other income/(expenses) | 20 | 72 | 86 | |
| Operating loss | (3,633) | (1,026) | (5,274) | |
| Loss of the period | (3,742) | (1,314) | (5,768) | |
| Net cash used in operations | 95 | (911) | (4,562) | |
| Net cash inflow/(outflow) of the period | 66,578 | (1,539) | (2,482) | |
| Cash and cash equivalents | 66,783 | 1,147 | 205 |
- Revenue over the period corresponded to royalties due on the sales of Sotalol IV made in the US by Hyloris’ distribution partner, AltaThera.
- Research and development expenses amounted to €1.2 million for the first half of 2020, an increase of €0.3 million compared to the same period of 2019 resulting from additional outsourced product development, pre-clinical and clinical expenses on our product candidates.
- General and administrative expenses amounted to €2.4 million, compared to €0.3 million in H1 2019. The €2.1 million increase was mainly driven by transaction costs associated to fund raises completed in H1 2020 and, to a lesser extent, to expenses associated to the ESOP warrants and to the strengthening of the management structure of the Company.
- Net operating cash flow was marginally up for H1 2020 (€0.1 million) compared to a cash burn of €0.9 million for H1 2019. Higher operating expenses incurred in H1 2020 were compensated by the proceeds of the sale of the rights of HY-REF-038 (in vial form) to Alter Pharma.
- Cash and cash equivalents increased to €66.8 million on June 30, 2020 compared to €0.2 million on December 31, 2019, resulting mainly from the issuance of convertible bonds in March and April 2020 for respectively €10.8 million and €4.4 million, and from the IPO completed on June 29, 2020 for €61.8 million.
Outlook for the remainder of 2020
Management believes that Hyloris is well positioned for the remainder of 2020 and beyond. The successful financing transactions undertaken during the first half of 2020 provide the Company with the required funding for: Development of the existing product portfolio until market release, the establishment of a commercial infrastructure in the United States for the commercialization of the IV Cardiovascular Portfolio under development, and the further expansion of the pipeline, both internally and through business development opportunities.
Hyloris Management anticipates several upcoming key milestones in the near term including:
- the commercial launch of Sotalol IV under the new extended label in the US
- the first European regulatory approvals of Maxigesic® IV
- FDA submission for market approval of Maxigesic® IV and Tranexamic Acid.
The Company’s operations were not materially affected by the ongoing COVID-19 pandemic.
Audit report
KPMG Réviseurs d’Entreprises represented by Olivier Declercq has reviewed the condensed consolidated interim financial statements of Hyloris SA as of and for the six-month period ended June 30, 2020. Their review was conducted in accordance with International Standard on Review Engagements 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” and their unqualified review report dated August 5, 2020 is attached to the interim financial information.
Rapport du commissaire
KPMG Réviseurs d’Entreprises représentée par Olivier Declercq a effectué l'examen limité des états financiers intermédiaires consolidés résumés de Hyloris SA pour la période de 6 mois arrêtée au 30 juin 2020. Leur examen a été effectué selon la norme ISRE 2410 « Examen limité d'informations financières intermédiaires effectué par l'auditeur indépendant de l'entité » et leur rapport d'examen sans réserve daté du 5 août 2020 est fourni en annexe aux informations financières intermédiaires.
CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
| ASSETS (in € thousand) | June 30, 2020 | December 31, 2019 | |
| Non-current assets | 2,757 | 2,245 | |
| Intangible assets | 2,648 | 2,138 | |
| Property, plant and equipment | 28 | 32 | |
| Right-of-use assets | 73 | 66 | |
| Financial assets | 9 | 9 | |
| Current assets | 69,056 | 3,739 | |
| Trade and other receivables | 427 | 333 | |
| Other financial assets | 6 | - | |
| Other current assets | 1,839 | 3,200 | |
| Cash and cash equivalents | 66,783 | 205 | |
| TOTAL ASSETS | 71,813 | 5,983 | |
| EQUITY AND LIABILITIES (in € thousand) | June 30, 2020 | December 31, 2019 | |
| Equity attributable to owners of the parent | 59,666 | (10,188) | |
| Share capital | 128 | 89 | |
| Share premium | 101,114 | 23,982 | |
| Retained earnings | (39,823) | (36,081) | |
| Other reserves | (1,753) | 1,822 | |
| Non-current liabilities | 7,948 | 22 | |
| Borrowings | 26 | 22 | |
| Other financial liabilities | 7,922 | - | |
| Current liabilities | 4,198 | 16,149 | |
| Borrowings | 47 | 44 | |
| Other financial liabilities | 409 | 13,130 | |
| Trade and other liabilities | 3,694 | 2,927 | |
| Current tax liabilities | 47 | 47 | |
| Total liabilities | 12,147 | 16,171 | |
| TOTAL EQUITY AND LIABILITIES | 71,813 | 5,983 |
CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE 6-MONTH PERIOD ENDED JUNE 30
| in € thousand | 2020 | 2019 |
| Revenue | 82 | 75 |
| Cost of sales | (109) | (37) |
| Gross profit | (27) | 38 |
| Research and development expenses | (1,172) | (819) |
| General and administrative expenses | (2,454) | (316) |
| Other operating income | 20 | 72 |
| Operating profit/(loss) | (3,633) | (1,026) |
| Financial income | 620 | 91 |
| Financial expenses | (729) | (380) |
| Profit/(loss) before taxes | (3,741) | (1,314) |
| Income taxes | (1) | - |
| PROFIT/(LOSS) FOR THE PERIOD | (3,742) | (1,314) |
| Other comprehensive income | - | - |
| TOTAL COMPREHENSIVE INCOME OF THE PERIOD | (3,742) | (1,314) |
| Profit/(loss) for the period attributable to the owners of the Company | (3,742) | (1,078) |
| Profit/(loss) for the period attributable to the non-controlling interests | - | (237) |
| Total comprehensive income for the period attributable to the owners of the Company | (3,742) | (1,078) |
| Total comprehensive income for the period attributable to the non-controlling interests | - | (237) |
| Basic and diluted earnings/(loss) per share (in €) | (0.21) | (0.07) |
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE 6-MONTH PERIOD ENDED JUNE 30, 2020
| in € thousand | Attributable to equity holders of the Company | Equity attributable to owners of the parent | Non-controlling interests | Total Equity | |||||
| Share capital | Share premium | Other reserves | Retained earnings | ||||||
| Share-based payment reserve | Cost of Capital | Other reserves | |||||||
| Balance at December 31, 2018 | 89 | 23,982 | 1,329 | - | 450 | (28,097) | (2,246) | (2,216) | (4,462) |
| Issuance of shares | - | - | - | - | - | - | - | - | - |
| Contribution by shareholder | - | - | - | - | 28 | - | 28 | - | 28 |
| Total comprehensive income | - | - | - | - | (1,078) | (1,078) | (237) | (1,314) | |
| Balance at June 30, 2019 | 89 | 23,982 | 1,329 | - | 478 | (29,175) | (3,296) | (2,453) | (5,748) |
| Balance at December 31, 2019 | 89 | 23,982 | 1,329 | - | 493 | (36,081) | (10,188) | - | (10,188) |
| Initial Public Offering | 29 | 61,784 | - | (3,656) | - | - | 58,156 | - | 58,156 |
| Issuance of convertible bonds | 4,531 | 4,531 | 4,531 | ||||||
| Conversion of convertible bonds | 10 | 15,347 | - | (102) | (4,585) | - | 10,671 | - | 10,671 |
| Amortized costs on shareholders loans | - | - | - | - | (5) | - | (5) | - | (5) |
| Share-based payments | - | - | 243 | - | - | - | 243 | - | 243 |
| Total comprehensive income | - | - | - | - | - | (3,742) | (3,742) | - | (3,742) |
| Balance at June 30, 2020 | 128 | 101,113 | 1,572 | (3,758) | 434 | (39,823) | 59,666 | - | 59,666 |
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE 6-MONTH PERIOD ENDED JUNE 30
| in € thousand | 2020 | 2019 |
| CASH FLOW FROM OPERATING ACTIVITIES | ||
| Net result for the period | (3,742) | (1,314) |
| Adjustments for: | ||
| Depreciation, amortization and impairments | 52 | 51 |
| Equity-settled share-based payment expense | 243 | - |
| Interest expenses on Convertible Bonds | 235 | - |
| Interest expenses on shareholders loans | 317 | 193 |
| Change in maturity of shareholders loans | (381) | - |
| Change in fair value of derivative instruments | (81) | - |
| Equity transaction costs | 1,408 | - |
| Income taxes | 1 | - |
| Other non-cash adjustments | (59) | 28 |
| Changes in working capital: | ||
| Trade and other receivables | (94) | 558 |
| Other financial assets | (6) | 3 |
| Other current assets | 1,361 | (1) |
| Trade and Other Payables | 723 | (976) |
| Other current liabilities | - | 1 |
| Other financial liabilities | 119 | 549 |
| Cash generated from operations | 96 | (911) |
| Taxes paid | (1) | - |
| Net cash generated from operating activities | 95 | (911) |
| CASH FLOW FROM INVESTING ACTIVITIES | ||
| Purchases of property, plant and equipment | - | - |
| Purchases of Intangible assets | (487) | (603) |
| Proceeds from other financial assets | - | - |
| Net cash provided by/(used in) investing activities | (487) | (603) |
| CASH FLOW FROM FINANCING ACTIVITIES | ||
| Reimbursements of shareholders loans | (8,050) | - |
| Proceeds from shareholders loans | 3,250 | - |
| Reimbursements of borrowings | (26) | (26) |
| Net proceeds from the Initial Public Offering | 56,803 | - |
| Net proceeds from the Convertible Bonds | 14,994 | - |
| Interests paid | (1) | (1) |
| Net cash provided by/(used in) financing activities | 66,970 | (26) |
| NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | 66,578 | (1,539) |
| CASH AND CASH EQUIVALENTS at beginning of the period | 205 | 2,687 |
| CASH AND CASH EQUIVALENTS at end of the period | 66,783 | 1,147 |
Conference Call Details
Hyloris will host a conference call on Thursday, 6 August at 2:00pm CEST accessible through the following numbers:
Event Plus Passcode: 2533728
Belgium, Brussels 02 793 3847
Belgium 0800 48 471
United States, New York 1 646 741 3167
United States 1 877 870 9135
United Kingdom 08 444 819 752
France 08 0510 1465
Netherlands 0800 023 5015
To ensure a timely connection, it is recommended that users register at least 10 minutes prior the scheduled start timing.
-Ends-
For more information, please contact:
Hyloris Pharmaceuticals
Stijn Van Rompay, CEO
+32 (0)4 346 02 07
contact@hyloris.com
Consilium Strategic Communications
Amber Fennell, Chris Welsh, Ashley Tapp Lucy Featherstone, Taiana De Ruyck Soares
+44 20 3709 5700
hyloris@consilium-comms.com
About Hyloris Pharmaceuticals SA
Based in Liège, Belgium, Hyloris is an early-stage innovative specialty pharmaceutical company focused on adding value to the healthcare system by reformulating well-known pharmaceuticals. Hyloris develops proprietary products it believes offer significant advantages compared to currently available alternatives, with the aim to address the underserved medical needs of patients, hospitals, physicians, payors and other stakeholders in the healthcare system. Hyloris’ portfolio spans three areas of focus: IV Cardiovascular, Other Reformulations and Established Market (high-barrier generics). Hyloris currently has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, commercialized through its partner AltaThera, and Maxigesic® IV, a non-opioid analgesic product for the treatment of pain, developed with the Company’s partner, AFT Pharmaceuticals. Additionally, Hyloris has 12 product candidates in various stages of development across the Company’s wider portfolio. Read more at www.hyloris.com. Hyloris stands for “high yield, lower risk” and relates to the 505(b)(2) regulatory pathway for product approval on which the Issuer focuses, but in no way relates or applies to an investment in the Shares.
1 IV stands for intravenous
2 Maxigesic® IV is a novel combination of paracetamol (also called acetaminophen in the United States) and ibuprofen in an intravenous form
3 Hyloris and Alter Pharma have some common shareholders which don’t have a controlling interest in Alter Pharma
4 Abbreviated New drug Application; application for a US generic drug approval for an existing licensed medication or approved drug